(Press-News.org) CHICAGO – An observational study that examined the comparative effectiveness of rhythm control vs. rate control drug treatment on mortality in patients with atrial fibrillation (a rapid, irregular heart beat) suggests there was little difference in mortality within four years of treatment, but rhythm control may be associated with more effective long-term outcomes, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
AF affects approximately 2.3 million Americans and 250,000 Canadians, and the condition has a complex therapy that may involve rate control agents, antiarrhythmic drugs, anticoagulant drugs and/or ablative techniques (use of a catheterization procedure to eliminate the anatomic source of the atrial fibrillation), according to study background.
"Controversy continues concerning the choice of rhythm control vs. rate control treatment strategies for atrial fibrillation (AF). A recent clinical trial showed no difference in five-year mortality between the two treatments. We aimed to determine whether the two strategies have similar effectiveness when applied to a general population of patients with AF with longer follow-up," the authors write as background.
Raluca Ionescu-Ittu, Ph.D., of the Harvard School of Public Health, Boston, and colleagues used population-based databases from Quebec, Canada, from 1999 to 2007 to select patients 66 years or older hospitalized with AF who did not have AF-related drug prescriptions in the year before they were hospitalized but received one within seven days of discharge.
"We found that with increasing follow-up time the mortality among the patients who newly initiated rhythm control therapy gradually decreased relative to those who initiated rate control drugs, reaching 23 percent reduction after eight years of follow-up," the authors comment.
The researchers note that recent clinical trials comparing the two treatments "concluded that there are no differences in mortality between the two treatment strategies."
"For the first four years after treatment initiation, our results in a population-based sample are similar to the results from the recent clinical trials. In addition, we found a tendency toward a long-term protective effect for rhythm control drugs. The long-term benefits of rhythm control drugs in AF found in this study need to be assessed in future studies," the researchers conclude.
(Arch Intern Med. Published online June 4, 2012. doi:10.1001/archinternmed.2012.2266. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: This research was supported by grants from the Canadian Institutes for Health Research (CIHR) to principal investigators. Some authors also disclosed support and affiliations. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Can Observational Data Trump Randomized Clinical Trial Results?
In an editorial, Thomas A. Dewland, M.D., and Gregory M. Marcus, M.D., M.A.S., of the University of California, San Francisco, write: "How do we best interpret this unexpected result given contrary evidence from prior randomized trials?"
"Although the findings of Ionescu-Ittu et al are provocative, they are insufficient to recommend a universal rhythm control strategy for all patients with AF. Randomization is a powerful tool that unfortunately cannot be reliably reproduced with statistical modeling," the authors conclude.
(Arch Intern Med. Published online June 4, 2012. doi:10.1001/archinternmed.2012.2332. Available pre-embargo to the media at http://media.jamanetwork.com.)
Editor's Note: Dr. Marcus is a consultant for In-Carda Therapeutics and has received research support from St. Jude Medical, Astellas and Gilead. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Louise Pilote, M.D., M.P.H., Ph.D., call Julie Robert at 514-934-1934 ext.71381 or email julie.robert@muhc.mcgill.ca. To contact corresponding editorial author Gregory M. Marcus, M.D., M.A.S., call Leland Kim at 415-502-9553 or email leland.kim@ucsf.edu.
### END
Study examines comparative effectiveness of rhythm control vs. rate control drug treatment
2012-06-05
ELSE PRESS RELEASES FROM THIS DATE:
Families of kids with staph infections have high rate of drug-resistant germ
2012-06-05
Family members of children with a staph infection often harbor a drug-resistant form of the germ, although they don't show symptoms, a team of researchers from Washington University School of Medicine in St. Louis has found.
The results are published in the June issue of Archives of Pediatrics & Adolescent Medicine.
The investigators focused on family members of nearly 200 children who had Staphylococcus aureus infections in the skin and soft tissue, in areas such as the nose, armpits and/or groin. They found that of the more than 600 household members who lived with ...
Joslin researchers find 'good fat' activated by cold, not ephedrine
2012-06-05
BOSTON -- June 4, 2012 -- Researchers at Joslin Diabetes Center have shown that while a type of "good" fat found in the body can be activated by cold temperatures, it is not able to be activated by the drug ephedrine.
The finding, published in today's issue of PNAS USA Early Edition, may lead to drugs or other methods aimed at activating the good fat, known as brown fat. When activated, brown fat burns calories and can help in the battle against obesity.
"We propose that agents that work similarly to cold in activating brown fat specifically can provide promising approaches ...
New statistical model lets patient's past forecast future ailments
2012-06-05
Analyzing medical records from thousands of patients, statisticians have devised a statistical model for predicting what other medical problems a patient might encounter.
Like how Netflix recommends movies and TV shows or how Amazon.com suggests products to buy, the algorithm makes predictions based on what a patient has already experienced as well as the experiences of other patients showing a similar medical history.
"This provides physicians with insights on what might be coming next for a patient, based on experiences of other patients. It also gives a predication ...
Hands-on research
2012-06-05
PASADENA, Calif.—A nuzzle of the neck, a stroke of the wrist, a brush of the knee—these caresses often signal a loving touch, but can also feel highly aversive, depending on who is delivering the touch, and to whom. Interested in how the brain makes connections between touch and emotion, neuroscientists at the California Institute of Technology (Caltech) have discovered that the association begins in the brain's primary somatosensory cortex, a region that, until now, was thought only to respond to basic touch, not to its emotional quality.
The new finding is described ...
Drug combination highly effective for newly diagnosed myeloma patients
2012-06-05
A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA.
The researchers, led by Andrzej J. Jakubowiak, M.D., Ph.D., professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center, found that combining carfilzomib, a next generation proteasome inhibitor, ...
Shape-shifting shell
2012-06-05
VIDEO:
As a retrovirus matures, the two parts of its shell protein (red and blue or yellow and blue) dramatically rearrange themselves, twisting and moving away from each other.
Click here for more information.
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have for the first time uncovered the detailed structure of the shell that surrounds the genetic material of retroviruses, such as HIV, at a crucial and potentially vulnerable stage ...
Filming life in the fast lane
2012-06-05
VIDEO:
A fruit fly embryo from when it was about two-and-a-half hours old until it walked away from the microscope as a larva, filmed by a new microscope developed at EMBL....
Click here for more information.
"This video shows a fruit fly embryo from when it was about two-and-a-half hours old until it walked away from the microscope as a larva, 20 hours later," says Lars Hufnagel, from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany. "It shows all ...
Export extravaganza
2012-06-05
Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, have conducted the first comprehensive census of human cells' export workers. In a study published online today in Nature Cell Biology, they found an unexpected variety of genes involved in transporting molecules to the cell membrane and beyond.
Using a combination of genetics and sophisticated microscopy, Rainer Pepperkok and colleagues systematically silenced each of our 22 000 genes, and observed to what extent this affected the cell's ability to transport a protein. They found that ...
From Paris Polyphenols to the IFT, HIDROX and CreAgri Receiving Continued Recognition
2012-06-05
Among the founding fathers of the biotechnology industry, Roberto Crea, PhD., founder and CEO of CreAgri Inc., is internationally acknowledged for the role he played in the successful establishment and growth of Genentech, Inc.--as one of the first four scientific founders of the legendary biotech company—and for his pioneering role in the production of many rDNA protein drugs from bacteria. Among other innovations, Dr. Crea is the inventor of the synthetic DNA process that led to the discovery of the first recombinant human insulin, Humulin , and many other pharmaceutical ...
A new multitarget molecule designed with high potential in future treatments for Alzheimer's disease
2012-06-05
Researchers at Universitat Autònoma de Barcelona (UAB), the Spanish National Research Council (CSIC) and the University of Barcelona (UB) have developed a multitarget molecule, ASS234, which according to the results of in vitro studies conducted, inhibits the aggregation of the ß-amyloid protein, involved in Alzheimer's disease. At the same time, ASS234 stimulates the cholinergic and monoaminergic transmission, key factors involved in the cognitive function. In addition, ASS234 is able to cross the blood–brain barrier with an elevated multipotent profile designed on basis ...